IP Verse

Pharmaceutical Formulations - EP4070788

The patent EP4070788 was granted to Gilead Sciences on Mar 22, 2023. The application was originally filed on Jun 29, 2016 under application number EP22176537A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP4070788

GILEAD SCIENCES
Application Number
EP22176537A
Filing Date
Jun 29, 2016
Status
Granted And Under Opposition
Feb 17, 2023
Grant Date
Mar 22, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ZENTIVADec 11, 2023REDDIE & GROSEADMISSIBLE

Patent Citations (8) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO0208241
DESCRIPTIONWO03016306
DESCRIPTIONWO2013025788
OPPOSITIONUS2007077295
OPPOSITIONWO2013025788
SEARCHWO2013116720
SEARCHWO2015022351
SEARCHWO2015196116

Non-Patent Literature (NPL) Citations (6) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- Curr. Opin. HIV AIDS, (20140000), vol. 9, no. 4, page 294
DESCRIPTION- S.M. BERGE et al., J. Pharma Sci., (19770000), vol. 66, no. 1, pages 1 - 19
OPPOSITION- Anonymous, "Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)", ClinicalTrials, NCT02345252, (20191216), pages 1 - 30, XP093118554
OPPOSITION- Richard J. Bastin et al, "salt selection and optimisation procedures for pharmaceutical new chemical entities", Organic Process Research & Development, American Chemical Society, US, US , (20000915), vol. 4, no. 5, doi:10.1021/op000018u, ISSN 1083-6160, pages 427 - 435, XP002728118
OPPOSITION- Peter J RUANE et al., "Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1-Positive Adults", J. Acquir. Immune. Defic. Syndr., (20130801), vol. 63, doi:10.1097/QAI.0b013e3182965d45, page 4, XP093107466
SEARCH- Gilead, "Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment", Press Release, (20150407), pages 1 - 2, URL: https://s24.q4cdn.com/804398512/files/doc_news/archive/fa11cc2a-1d4e-417e-9419-e7c955a8edef.pdf, (20201207), XP055757389 [A] 1-13 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents